Harderwijk, the Netherlands and El Segundo, CA, USA – March 29, 2017 – GENALICE and BioDiscovery announce a co-marketing partnership to offer their products together as a turn-key end-to-end solution for the use of next-generation sequencing (NGS) data to interpret genomes. GENALICE provides an ultra-fast and highly accurate secondary analysis suite that seamlessly connects to BioDiscovery’s tertiary informatics and genomics interpretation system, NxClinical.
“The GENALICE and BioDiscovery co-marketing partnership is a response to the rapidly growing volumes and usage of NGS data, which highlights the urgent need for faster processing and interpretation technologies. Only few solutions are on the market that truly speed up read mapping, variant calling and interpretation. Our partnership offers a new reality in which large volumes can be analyzed close to real time, enabling truly important data interpretation and data mining of genomic variants of interest in a cost-effective manner. This game-changing solution in big data processing will have a significant positive impact in clinics towards the goal of achieving precision medicine in complex DNA disease areas, for instance in oncology” GENALICE’s Commercial Director Michelle Meijer comments.
“BioDiscovery’s reputation as the gold standard for array-based cytogenomic analysis and interpretation software is based on over a decade of high-quality cutting-edge systems used by hundreds of labs across the globe. With our recent introduction of NxClinical 3.0, we have expanded this capability into molecular genetics with complete management of NGS generated variant analysis and interpretation in combination with CNV - a truly unique feature,” says Dr. Soheil Shams, President of BioDiscovery. “We are very excited about working with GENALICE to offer many of our customers a complete end-to-end solution starting from raw read files straight from the equipment.”
GENALICE MAP and NxClinical seamlessly work together offering customers, who want the advantage of the combined system, a reduction of NGS big data bottlenecks with unmatched visualizations and integrated interpretation of sequence variants and Copy Number Variations (CNVs). GENALICE MAP is the accelerator that improves the process of aligning and calling genomes, whilst NxClinical focuses on providing an enterprise-wide multi-user database enabling reviewing and reporting combined data of Single Nucleotide Variants (SNVs), INDELs, and CNVs. A single database system is used for NGS and microarray data sets. The two products create a complementary workflow that eliminates many of the frustrations of wrangling NGS data today.
“We are excited to present our proof of concepts during a joint Industry Workshop, entitled ‘Innovative Approaches for High Quality Somatic Mutation Detection and Interpretation Delivering Fastest Turnarounds’ at the AMP Global conference in Berlin next week. On Wednesday, April 5, our companies will demonstrate customer cases of the combined workflow, somatic calling and CNV pipeline comparisons,” says Michelle.
GENALICE is a highly innovative genomics big data company. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis that can operate on general-purpose hardware. GENALICE has introduced the first NGS data processing pipeline with true Population Power and is leading the way in Somatic Variant Calling. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome and exome sequencing for biomarker discovery and medical application. More information on GENALICE and GENALICE MAP can be found at www.genalice.com.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company’s mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care. For more information on BioDiscovery, visit www.biodiscovery.com
Please note the following: The BioDiscovery software tools referenced are designed to assist clinical researchers and are not intended as primary diagnostic tools. It is each lab’s responsibility to use the software in accordance with internal policies as well as in compliance with applicable regulations.
For more information, please contact:
GENALICE B.V. BioDiscovery, Inc.
Dr. Michelle Meijer Shalini Verma
Commercial Director MarCom Manager
+31 88 1221 000 310-414-8100